A new obesity treatment which could cause fewer side effects has demonstrated a strong pharmacokinetic (PK) profile in preclinical trial. 

The treatment, developed by pharmaceutical company Nanexa AB, reportedly indicated a very low ratio between the maximum and minimum plasma concentration over the dosing interval following once-monthly subcutaneous administration. 

The company’s preclinical results show clear dose-linearity, and significantly improved bioavailability compared with Nanexa’s earlier liraglutide formulations. 

With the treatment developed using Nanexa’s proprietary PharmaShell drug delivery platform, preclinical results show plasma concentration is significantly more stable than that typically achieved with weekly administration of the marketed product Wegovy (semaglutide). 

By avoiding the sharp plasma concentration spikes often linked to nausea and other gastrointestinal symptoms, Nanexa believes its formulation may offer a more tolerable initiation and maintenance profile for patients. 

“These latest results represent a major milestone for Nanexa,” said David Westberg, CEO of Nanexa.  

“Demonstrating such a long release profile and low ratio between the maximum and minimum plasma concentration for monthly administration is exceptional and highlights how powerful the PharmaShell technology can be for complex molecules like semaglutide.  

“We are excited about this data which will strengthen our position to secure commercial partnerships.”